Perseus Proteomics Inc.
TSE:4882 Stok Raporu
Perseus Proteomics Bilanço Sağlığı
Finansal Sağlık kriter kontrolleri 6/6 Perseus Proteomics şirketinin toplam hissedar öz sermayesi ¥1.9B ve toplam borcu ¥0.0 olup, bu da borç-öz sermaye oranını 0% seviyesine getiriyor. Toplam varlıkları ve toplam yükümlülükleri sırasıyla ¥2.2B ve ¥300.0M dir.
Anahtar bilgiler Faiz karşılama oranı n/a Nakit JP¥2.13b Eşitlik JP¥1.91b Toplam yükümlülükler JP¥300.00m Toplam varlıklar JP¥2.21b
Son finansal sağlık güncellemeleri
Tüm güncellemeleri göster
Perseus Proteomics Inc. Announces Registration of Patent Jointly Filed with Juntendo University Sep 27
Perseus Proteomics Inc. to Report Q2, 2025 Results on Nov 14, 2024 Aug 27
First quarter 2025 earnings released: JP¥15.77 loss per share (vs JP¥35.89 loss in 1Q 2024) Aug 19
Full year 2024 earnings released: JP¥93.65 loss per share (vs JP¥66.84 loss in FY 2023) Jun 25
Full year 2024 earnings released: JP¥93.65 loss per share (vs JP¥66.84 loss in FY 2023) May 21
Perseus Proteomics Inc., Annual General Meeting, Jun 20, 2024 May 17
Perseus Proteomics Inc. Announces on Delay in the End of Phase I Clinical Trial for Polycythemia Vera May 11
New minor risk - Shareholder dilution Apr 27 Perseus Proteomics Inc. announced that it has received ¥1.566 million in funding from Barclays Bank PLC (Tokyo Branch) Mar 07
Perseus Proteomics Inc. to Report Fiscal Year 2024 Results on May 15, 2024 Mar 02
Third quarter 2024 earnings released Feb 16
Perseus Proteomics Inc. Announces on Delay in the End of Phase I Clinical Trial for Polycythemia Vera Feb 02
Perseus Proteomics Inc. to Report Q3, 2024 Results on Feb 14, 2024 Nov 30
Second quarter 2024 earnings released Nov 14
Perseus Proteomics Inc. Announces Completion of Patients Enrollment in Phase I Clinical Trial for Polycythemia Vera (PV) Oct 21
Perseus Proteomics Inc. Announces Sales Launch of New Antibodies/Reagents Oct 11
Perseus Proteomics, Inc. Announces Provision of Antibody Research Support Service Through Single Cell Cloning Technology Sep 28
Perseus Proteomics Inc. Announces on Dosing of the First Patient in Phase I/II Clinical Trial for Aggressive NK-Cell Leukemia Sep 23
Perseus Proteomics Inc. to Report Q2, 2024 Results on Nov 13, 2023 Sep 02
First quarter 2024 earnings released: JP¥35.89 loss per share (vs JP¥17.01 loss in 1Q 2023) Aug 16
Perseus Proteomics Inc. to Report Q1, 2024 Results on Aug 14, 2023 Jun 03
Perseus Proteomics Inc. Announces the Interim Report of Phase I Clinical Trial of PPMX-T003 May 30
Full year 2023 earnings released May 13
Perseus Proteomics Inc., Annual General Meeting, Jun 23, 2023 May 13
Third quarter 2023 earnings released: JP¥16.92 loss per share (vs JP¥10.12 loss in 3Q 2022) Feb 15
Perseus Proteomics Inc. Provides Consolidated Earnings Guidance for the Fiscal Year Ending March 31, 2023 Feb 14
Perseus Proteomics Inc. Announces Extension of Phase I Clinical Trial of PPMX-T003 among Polycythemia Vera Patients Feb 07
Perseus Proteomics Inc. to Report Q3, 2023 Results on Feb 13, 2023 Nov 27
Second quarter 2023 earnings released: JP¥13.86 loss per share (vs JP¥10.12 loss in 2Q 2022) Nov 16
No independent directors Nov 16
Second quarter 2023 earnings released: JP¥13.86 loss per share (vs JP¥10.12 loss in 2Q 2022) Nov 13
Perseus Proteomics Inc. Provides Earnings Guidance for the Year Ending March 31, 2023 Nov 12
Perseus Proteomics Inc. to Report Q2, 2023 Results on Nov 11, 2022 Sep 02
Perseus Proteomics Inc. Announces First/Second Patients Dosed in Phase I Clinical Trial Among Polycythemia Vera (Pv) Patients Aug 25
Perseus Proteomics Inc. Provides Earnings Guidance for the Year Ending March 31, 2023 Aug 13
Perseus Proteomics Inc. to Report Q1, 2023 Results on Aug 12, 2022 Jun 02
Perseus Proteomics Inc., Annual General Meeting, Jun 23, 2022 May 14
No independent directors Apr 27
Perseus Proteomics Inc. to Report Fiscal Year 2022 Results on May 13, 2022 Apr 08
Perseus Proteomics Inc. Provides Earnings Guidance for the Year Ending March 31, 2022 Feb 16
Perseus Proteomics Inc. Announces Initiation of Phase I Clinical Trial in Polycythemia Vera Patients Sep 15
Finansal Durum Analizi
Kısa Vadeli Yükümlülükler: 4882 'nin kısa vadeli varlıkları ( ¥2.2B ) kısa vadeli yükümlülüklerini ( ¥108.0M ) aşıyor.
Uzun Vadeli Yükümlülükler: 4882 şirketinin kısa vadeli varlıkları ( ¥2.2B ) uzun vadeli yükümlülüklerini ( ¥192.0M ) aşmaktadır.
Borç-Özkaynak Tarihçesi ve Analizi
Borç Seviyesi: 4882 borçsuzdur.
Borcun Azaltılması: 4882 son 5 yıldır borcu bulunmamaktadır.
Nakit Pist Analizi Geçmişte ortalama olarak zarar eden şirketler için, en az 1 yıllık nakit akışına sahip olup olmadıklarını değerlendiriyoruz.
İstikrarlı Nakit Pisti: 4882 şirketinin mevcut serbest nakit akışına göre bir yıldan fazla yetecek nakit pisti bulunmaktadır.
Tahmini Nakit Akışı: 4882 serbest nakit akışı her yıl % 28.1 1.9 yıl yetecek nakit akışına sahip olacaktır.
Sağlıklı şirketleri keşfedin Simply Wall St™ Simply Wall Street Pty Ltd (ACN 600 056 611), is a Corporate Authorised Representative (Authorised Representative Number: 467183) of Sanlam Private Wealth Pty Ltd (AFSL No. 337927). Any advice contained in this website is general advice only and has been prepared without considering your objectives, financial situation or needs. You should not rely on any advice and/or information contained in this website and before making any investment decision we recommend that you consider whether it is appropriate for your situation and seek appropriate financial, taxation and legal advice. Please read our Financial Services Guide before deciding whether to obtain financial services from us.
{"enabled":true,"variant":{"name":"display-ssr-flag","enabled":true,"feature_enabled":true,"featureEnabled":true},"flagsReady":true,"flagsError":null}